News & Events about Evolus Inc.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced the commercial launch of Nuceiva (botulinum toxin type A) in Italy. The product is now available for direct order and delivery to customers. Nuceiva is approved by the European...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the completion of its Phase 2 clinical study evaluating an extra-strength dose for extended duration of Jeuveau (prabotulinumtoxinA-xvfs), its flagship...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida. Event: Barclays...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has commenced the commercial launch of Nuceiva (botulinum toxin type A) in Germany and Austria, and is now available for direct order and delivery to customers...